Monitor this situation.

Unsubscribe anytime.

[SITUATION] · [ACTIVE] · [TECHNOLOGY]

2 clusters · 5 sources · 3 days · First seen 4 days ago · Last updated about 23 hours ago

Lunit medical AI oncology research collaborations

Overview

Medical AI company Lunit has announced several research initiatives to advance cancer treatment. At the ESMO 2026 Congress, the company will present findings from its ‘AI forHER’ project, a collaboration with AstraZeneca, Daiichi Sankyo, and the Institut de Cancérologie de l’Ouest. This project uses the Lunit SCOPE biomarker platform to analyze HER2 expression in breast cancer patients.

Lunit has also entered a research agreement with Summit Therapeutics to apply its Lunit SCOPE IO platform to immuno-oncology development programs. This partnership aims to use AI-powered pathology to analyze H&E-stained whole-slide images to characterize tumor microenvironment features. The research is intended to support the development of ivonescimab, a first-in-class PD-1 / VEGF bispecific antibody, by assisting in biomarker discovery and patient stratification.

Entities

Summit Therapeutics · AstraZeneca · Lunit · Ivonescimab · Daiichi Sankyo

Timeline

about 23 hours ago

[TECHNOLOGY] 4 sources
Lunit partners with Summit Therapeutics for AI biomarker research
South Korean AI medical firm Lunit is collaborating with US-based Summit Therapeutics to use AI pathology to develop biomarkers for the immunotherapy drug ivonescimab.
4 days ago

[TECHNOLOGY] 2 sources
Lunit announces research collaborations in AI oncology and immuno-oncology
Lunit is expanding its AI oncology footprint through research with AstraZeneca and Daiichi Sankyo on HER2 expression and a new agreement with Summit Therapeutics to analyze tumor microenvironments.

Sources

blockchainseoul.kr · m.imaeil.com · marketersmedia.com · thebionews.net · venturesquare.net